1337564-23-4

Basic information

• Product Name: 2-[7-(2,3,6-trifluorobenzyl)imidazo[1,5-b]pyridazin-5-yl]-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidin-4-amine
• Synonyms: 2-[7-(2,3,6-trifluorobenzyl)imidazo[1,5-b]pyridazin-5-yl]-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidin-4-amine
• CAS NO: 1337564-23-4
• Molecular Weight: 464.453
• Mol File: 1337564-23-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-[7-(2,3,6-trifluorobenzyl)imidazo[1,5-b]pyridazin-5-yl]-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[7-(2,3,6-trifluorobenzyl)imidazo[1,5-b]pyridazin-5-yl]-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidin-4-amine(1337564-23-4)
• EPA Substance Registry System: 2-[7-(2,3,6-trifluorobenzyl)imidazo[1,5-b]pyridazin-5-yl]-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidin-4-amine(1337564-23-4)

Safety Data

• Hazardous Substances Data: 1337564-23-4(Hazardous Substances Data)

Upstream product

• 53896-49-4 pyridazine-3-carbonitrile 
• 1337566-93-4 C₁₇H₁₀BrF₃N₆ 
• 844891-04-9 1,3,5-trimethylpyrazole-4-boronic acid pinacol ester 
• 106861-14-7 2-[(4-methylphenyl)sulfonyl]-2,3-dihydropyridazine-3-carbonitrile 
• 1228788-26-8 C₁₃H₁₀F₃N₃O 
• 1228788-27-9 C₁₃H₈F₃N₃ 
• 1228788-28-0 C₁₃H₇F₃IN₃ 

Relevant articles and documents

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.